Pulmatrix
Pulmatrix is a biotechnology company founded in 2003 that developed inhaled therapies for infectious and progressive respiratory diseases using its iSPERSE dry-powder drug delivery platform. Its investigational assets include treatments for migraine, chronic obstructive pulmonary disease and allergic bronchopulmonary aspergillosis. It currently operates as a virtual company and is seeking to monetize its legacy clinical assets.
Key facts
| CAGE Code | 53TY3 |
|---|---|
| Legal Name | Pulmatrix, Inc. |
| Company Operating Status | Active |
| Full Address | 99 Hayden Avenue, Suite 390 Lexington, MA 02421, US |
| Previous Name | Ruthigen, Inc. |
| Public/Private | Private |
| Ticker Symbol | PULM |
| Wellfound ID | pulmatrix |
Contact details
Email and phone for Pulmatrix are available to signed-in members of CliffBio.
Sign in to view